Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab
Background: Breast cancer is the most common cancer among the female population and its prevalence is increasing worldwide. Trastuzumab (Herceptin) therapy improves prognosis in HER2 positive patients, but Heart Failure (HF) is one of its known complication. In this study we aimed to assess potential benefits of prophylactic carvedilol therapy in patients receiving Herceptin.
Method: 65 HER2 positive breast cancer patients were enrolled in the study. All of the patients received Herceptin. 27 patients also received carvedilol 6.25 mg twice daily and 38 patients had usual care. Echocardiography was performed at baseline and after 3 months in both groups and changes in cardiac function parameters were compared between two groups.
Result: After 3 months, LA volume index (p value = 0.012), TAPSE (p value = 0.009), Tei index (p value = 0.015) and Lateral Longitudinal Strain (p value = 0.024) were significantly better in patients receiving carvedilol.
Conclusion: Carvedilol can be effective in prevention of systolic and diastolic dysfunction following Herceptin therapy.